Replimune (REPL) Debt Ratio (2023 - 2025)

Replimune's (REPL) quarterly Debt Ratio came in at 0.14 in Q4 2025, up 87.52% year-on-year from 0.08 in Q4 2024, and up 17.79% quarter-over-quarter from 0.12 in Q3 2025.

Replimune (REPL) Debt Ratio (2023 - 2025) Analysis & Trends

Replimune has disclosed Debt Ratio across 3 years of filings, most recently posting 0.14 for Q4 2025.

  • Debt Ratio for Q4 2025 came in at 0.14, up 87.52% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.14 (up 87.52% YoY), and the FY2025 annual result was 0.08, down 8.44% from the prior year.
  • Debt Ratio came in at 0.14 for Q4 2025 at Replimune, up from 0.12 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.14 in Q4 2025 to a low of 0.04 in Q1 2023.
  • The 3-year median for Debt Ratio is 0.09 (2024), against an average of 0.09.
  • Across the five-year window, Debt Ratio surged 107.36% in 2024 and declined 8.44% in 2025, its largest moves.
  • Replimune's Debt Ratio stood at 0.04 in 2023, then surged by 71.85% to 0.08 in 2024, then soared by 87.52% to 0.14 in 2025.
  • The last three Debt Ratio figures came in at 0.14 (Q4 2025), 0.12 (Q3 2025), and 0.1 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn 0.18
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn -
9 Abivax 95.45 Bn 95.45 Bn - -
10 Replimune 848.00 Mn 578.86 Mn - 0.14

Historic Data

Download Data
DateValue
Dec 31, 2025 0.14
Sep 30, 2025 0.12
Jun 30, 2025 0.10
Mar 31, 2025 0.08
Dec 31, 2024 0.08
Sep 30, 2024 0.09
Jun 30, 2024 0.08
Mar 31, 2024 0.09
Mar 31, 2023 0.04